Anti-NMDA Receptor Antibody Positivity and Presentations Without Seizure, Involuntary Movement, Hypoventilation, or Tumor: A Systematic Review of the Literature
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis may remain undiagnosed and untreated with immunotherapy. To investigate specific features and responses to immunotherapy of atypical anti-NMDAR antibody positivity patients, the authors reviewed and evaluated previous case reports/series including patients without seizure, involuntary movement, hypoventilation, or tumor. Of 22 patients identified, 21 responded to immunotherapy. Two patients had neurological/motor symptoms with few/no psychiatric/cognitive symptoms, and eight had both. Twelve patients presented with psychiatric/cognitive symptoms with few/no neurological/motor symptoms, and ≥1 had memory impairment, catatonia, abnormal MRI or electroencephalogram results. The authors recommend lumbar puncture and examination of anti-NMDAR antibodies for patients with these features.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was formally recognized in 2007 as a specific type of autoimmune encephalitis.1 This encephalitis is an immune-mediated disorder associated with immunoglobulin G (IgG) antibodies to the GluN1 subunit of the NMDAR and is most common in young female patients with ovarian teratomas.2 In the prodromal phase, approximately 70% of patients with anti-NMDAR encephalitis present with nonspecific flu-like symptoms such as nausea, vomiting, fever, headache, and fatigue for about 0–2 weeks. In the progressive phase, typical presentations include initial psychiatric symptoms followed by seizures, memory deficits, decreased level of consciousness, movement abnormalities (e.g., catatonia, dyskinesia, and chorea), autonomic instability, and central hypoventilation.3 Within the first 4 weeks after symptom onset, most patients (87%) develop typical symptoms irrespective of their age. Immunotherapy and tumor resection (if present) typically lead to positive outcomes, with most patients returning to baseline functions.4
Anti-NMDAR encephalitis has now been described in patients of both sexes ranging in age from less than 1 year to over 80 years,4 and the course of this disorder may be extremely variable. Cases presenting with psychiatric/cognitive symptoms with few or no neurological/motor symptoms have been reported. Of 571 patients with anti-NMDAR encephalitis, 23 (4%) developed isolated psychiatric episodes; of these, five (0.9%) presented at the first episode of encephalitis and 18 at relapse of encephalitis. Of these 23 patients, 83% completely or substantially recovered after immunotherapy and tumor resection (if any).5 We previously reported an atypical case of anti-NMDAR encephalitis presenting with first-episode psychosis and resistance to antipsychotic treatment, without neurological symptoms or tumor, where disease improved with immunotherapy.6
Generally, three out of four patients with anti-NMDAR encephalitis do not consult a general health care service before seeking treatment at a psychiatric department.2 If patients do not present with typical manifestations, this treatable disorder may remain undiagnosed in psychiatric care settings, which may lead to a delay in the detection of anti-NMDAR antibodies and treatment with immunotherapy. The diversity of clinical characteristics of anti-NMDAR encephalitis and the response to immunotherapy in cases with atypical manifestations remains unclear. We therefore conducted a systematic review of case reports and series of atypical presentations associated with anti-NMDA receptor antibody positivity to investigate the specific symptoms or patterns of patients presenting with psychiatric/cognitive symptoms with few or no neurological/motor symptoms.
Materials and Methods
Search
This systematic review followed the PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses] guidelines. We reviewed previous case reports and series of atypical presentations associated with anti-NMDA receptor antibody positivity. We searched MEDLINE (PubMed) to perform a systematic review of the literature published prior to December 31, 2015, using the following search terms: (“N-methyl-D-aspartate receptor” or “NMDA receptor” or “NMDAR”) and (“encephalitis” or “antibody” or “antibodies”). The electronic search was supplemented by a manual search of reference lists of relevant publications. Only articles in English or Japanese were included.
Study Selection
The diagnosis of anti-NMDA receptor antibody positivity was made based on the detection of IgG antibodies against the NR1 subunit of the NMDAR in serum or cerebrospinal fluid (CSF).2 All articles were evaluated to determine whether case reports without seizure, involuntary movement, hypoventilation, and tumor, which we defined as atypical presentations, were included. We also included patients with psychotropic-induced or catatonia-related movement disorders and who were treated with immunotherapy. We excluded patients who had classic presentations at the first episode of encephalitis but experienced atypical presentations during a relapse of encephalitis. Because the inclusion criteria required confirmation by clinical characteristics and treatment of each patient, we needed to eliminate cohort studies. If that was not possible, we carefully considered each case as an alternative.
Data Extraction
The following data were collected from all articles: author, publication year, sex, age, duration of illness, initial diagnosis, comorbidity, psychiatric/cognitive symptoms, neurological/motor symptoms, abnormal CSF results, MRI and electroencephalogram (EEG) findings, anti-NMDAR antibodies in serum and CSF, immunotherapy, time from initial immunotherapy until clinical improvement, and clinical outcome of patients.
Results
Literature Search
The literature search using the MEDLINE (PubMed) electronic database yielded a total of 2,057 citations. Of these, 322 case reports or series were fully inspected, and 301 were removed from analysis for the following reasons: presence of seizure, involuntary movement, hypoventilation, or tumor (266 articles); case series without individual case reports (18 articles); immunotherapy not administered (12 articles); and absence of IgG anti-NMDAR antibody (five articles). Finally, our review identified 21 articles (22 patients) with atypical anti-NMDA receptor antibody positivity treated with immunotherapy (Figure 1).5–25 The publication years were 2011 (N=2), 2012 (N=2), 2013 (N=6), 2014 (N=4), and 2015 (N=8) (Table 1).
FIGURE 1. Flowchart of the Literature Searcha
a IgG: immunoglobulin G; NMDAR: N-methyl-d-aspartate receptor.
| Case No./Author/Publication Year | Sex/Age (Years) | Duration of Illness | Initial Diagnosis/Comorbidity | Psychiatric and Cognitive Symptoms | Neurological and Motor Symptoms | Abnormal Results for CSF/MRI/EEG | Anti-NMDAR/Abnormal Serum CSF | Immunotherapy (Order of Treatment) | Time From Initial Immunotherapy Until Clinical Improvement | Immunotherapy Response |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Zandi et al./20117 | Male/19 | 3 months | SCZ/– | Auditory hallucinations, thought disorder, grandiose delusions, deficits of recall and verbal fluency | Nil | NA/NA/NA | +/NA | PE, steroids | 3 weeks | Very much improved |
| 2. Suzuki et al./20118 | Female/70 | 6 months | NA/SSc | Dementia (10/30 on MMSE) | Ataxia, tremor, rigidity, muscle weakness | +/+/ NA | +/+ | Steroids, CTX | NA | Very much improved |
| 3. Lekoubou et al./20129 | Female/34 | 1 month | ADEM/– | Psychomotor agitation, echolalia and echopraxia, incoherent speech, delusions of persecution | Walking difficulties, disorientation, cerebellar ataxia, hemiparesis | +/+/NA | NA/+ | IVIg, steroids, RTX | <6 months | Much improved |
| 4. Lebon et al./201210 | Female/16 | 2 months | Primary psychotic disorder/– | Mutism, refusal to eat, infantile behavior, auditory hallucinations, incoherent speech, memory impairment, executive deficit, attention deficit | Nil | –/–/+ | +/NA | Steroids, IVIg | 9 months | Very much improved |
| 5. Yuan et al./201311 | Female/22 | 3 weeks | NA/– | Affective lability, grandiose thoughts, paranoid delusion, auditory and visual hallucinations, deficits of verbal fluency, visuospatial deficit, hemispatial neglect, memory impairment | Nil | +/–/+ | NA/NA (Positive in serum or CSF or both) | Steroids, IVIg, PE, RTX | 6 months | Much improved |
| 6. Yau et al./201312 | Female/5 | 1 week | NA/– | Fluctuating level of consciousness, mutism, impaired speech, irritability | Nil | +/–/+ | –/+ | IVIg | 1 week | Very much improved |
| 7. Tüzün et al./201313 | Female/42 | 2 weeks | NA/– | Mild Executive Deficit | Double vision, difficulty walking, limited vertical gaze | +/+/– | +/+ | Steroids | 2 months | Very much improved |
| 8. Leypoldt et al./201314 | Male/24 | 1 day | Relapse of HSVE/– | Mania, irritability, racing thoughts, pressured speech, memory impairment, attention deficit | Nil | +/+/– | +/+ | Steroids | 1 week | Much improved |
| 9. Kayser et al./20135 | Male/19 | 2–3 months | Demyelinating disease/– | Aggression, excessive eye blinking, grandiosity, delusional thinking | Nil | +/+/– | +/NA | Steroids, AZA | 9 months | Very much improved |
| 10. Kayser et al./20135 | Female/20 | NA | NA/– | Delusion, depression | Nil | +/+/NA | +/+ | Steroids, IVIg, RTX, MMF | NA | Very much improved |
| 11. Kuppuswamy et al./201415 | Male/35 | 2 weeks | Primary psychotic disorder/– | Depression, suicidality, grandiosity, impulsivity, mutism, posturing, staring, ambitendency | Nil | –/–/– | +/+ | Steroids, PE, AZA | 4 months | Very much improved |
| 12. Finke et al./201416 | Male/67 | 2 weeks | HaNDL/– | Confusion, agitation, aggressiveness, retrograde amnesia, memory impairment, attention deficit | Transient hemiparesis, transient aphasia | +/–/+ | –/+ | Steroids, PE, AZA | 6 weeks | Much improved |
| 13. Byrne et al./201417 | Male/4 | 2 days | NA/– | Confusion, agitation | Dysphasia, coma | –/+/+ | +/NA | Steroids | 4 days | Very much improved |
| 14. Takeda et al./201418 | Male/35 | 6 days | Herpes encephalitis/– | Delirium, violent behavior, delusions, disorientation | Diplopia, paraparesis, hypoesthesia, ptosis | +/+/NA | NA/+ | Steroids, PE, CTX | 12 months | Much improved |
| 15. Fleischmann et al./201519 | Female/37 | 5.5 years | NA/MS and SS | Delusions, bizarre behavior, aggressiveness, memory impairment, Dementia (14/30 on MMSE), disorientation, executive deficit | Gait ataxia, dysarthria | +/+/ NA | +/+ | Steroids, AZA, CTX, NTL, PE, MTX | Nonresponse | Death (urosepsis) |
| 16. Cuende et al./201520 | Female/61 | 3 months | NA/RA | Memory loss | Dizziness, unsteady gait, muscle weakness, speech problems | +/–/NA | +/+ | IVig | NA | Very much improved |
| 17. Kruse et al./201521 | Female/14 | NA | NA/– | Anxiety, depressed mood, disinhibited and disorganized behavior, reduced verbal output, slow speech, learning difficulty | Transient arm numbness, difficulty with complex motor tasks | +/–/+ | –/+ | NA | NA | Very much improved |
| 18. Sühs et al./201522 | Female/23 | 2 years | Psychiatric disorder/– | Fearful behavior, stereotypical repetitive movements, loss of orientation, memory impairment, executive deficit | Nil | +/–/+ | +/NA | Steroids | 1 month | Very much improved |
| 19. Orengo et al./201523 | Female/29 | 3 months | NA/serum aquaporin-4 antibody positive | Anorexia, abulia, mutism, immobility, nonsensical speech, memory impairment | Imbalance and vertigo, facial numbness, ataxia | +/+/NA | –/+ | Steroids, PE, RTX | NA | Much improved |
| 20. Gahr et al./201524 | Male/34 | 1 week | Psychotic mania/– | Impulsivity, aggressiveness, hostility, dysphoric mania paranoid ideation hyper-religiosity | Nil | +/+/NA | +/+ | Steroids, IVIg | NA | Very much improved |
| 21. Senda et al./Epub ahead of print 20156 | Female/33 | 2 years | SCZ/HT | Auditory and visual hallucination, delusions of persecution, delusion of control agitation, memory impairment, executive deficit | Nil | –/–/– | NA/+ | Steroids, IVIg | 3 months | Much improved |
| 22 Lalanne et al./201525 | Female/31 | NA | Psychotic depression | Melancholia, depression, cenesthopathy, memory impairment, attention deficit | Nil | NA/+/+ | NA/+ | Steroids, IVIg | 5 weeks | Very much improved |
a
Ab: antibody, ADEM: Acute disseminated encephalomyelitis, ADHD: attention deficit hyperactivity disorder, AZA: azathioprine, CSF: cerebrospinal fluid, CTX: cyclophosphamide, EEG: electroencephalogram, HaNDL: headache with neurological deficits and cerebrospinal fluid lymphocytosis, HSVE: herpes simplex virus-1 encephalitis, HT: Hashimoto's thyroiditis, IVIg: intravenous immunoglobulin, MMF: mycophenolate mofetil, MMSE: Mini-Mental State Examination, MS: multiple sclerosis, MRI: magnetic resonance imaging, MTX: mitoxantrone, NA: not available, NMDAR: N-methyl-D-aspartate receptor, NTL: natalizumab, PE: plasmapheresis, RA: rheumatoid arthritis, RTX: rituximab, SCZ: schizophrenia, SSc: systemic sclerosis SS: Sjögren's syndrome.
Clinical Characteristics
Table 1 shows the clinical characteristics of 22 patients, including eight male and 14 female patients. The age range was 4–70 years (mean, 30.6 years; median, 30 years). The mean±standard deviation (range) duration of illness (N=19) was 31.3±69.2 (0.15–286) weeks. Seven patients were initially diagnosed with primary psychiatric disorders. Five patients had other comorbid autoimmune disorders/antibodies: systemic sclerosis (N=1), multiple sclerosis and Sjögren's syndrome (N=1), rheumatoid arthritis (N=1), aquaporin-4 antibody positive (N=1), and Hashimoto’s thyroiditis (N=1). Twelve patients presented with psychiatric/cognitive symptoms with few or no neurological/motor symptoms. Two patients had few or no psychiatric/cognitive symptoms but did have neurological/motor symptoms. The remaining eight patients showed both types of symptoms. The distribution of psychiatric indications was psychotic symptoms (N=10), affective symptoms (N=8), and catatonic symptoms (N=6). Of the 12 patients who presented with psychiatric/cognitive symptoms with few or no neurological/motor symptoms, six (50%) had one of the following: memory impairment, catatonia, or abnormal MRI or EEG results, and six (50%) had two or more of these symptoms.
Test Results
Of 22 patients, abnormal CSF, MRI, and EEG results were confirmed in 16 (pleocytosis, N=12; elevated protein, N=8; oligoclonal band, N=8; unknown, N=2), 12, and 8 patients, respectively. In two patients, the results of all three tests were normal. Of 16 patients with anti-NMDAR antibodies in the CSF, serum antibodies were negative in four patients, positive in eight patients, and unknown in four patients.
Immunotherapy and Outcome
The frequencies of immunotherapy, in order of declining frequency were: steroids, 19/21; intravenous immunoglobulin, 9/21; plasmapheresis, 7/21; azathioprine, 4/21; rituximab, 4/21; cyclophosphamide, 3/21; and others, 3/21. The immunotherapy of case 17 was unspecified. Fourteen patients (64%) fully recovered, seven patients (32%) were much improved by immunotherapy, and one patient died (urosepsis). The time from initial immunotherapy until clinical improvement ranged from 4 days to 12 months (N=14; mean, 15.4 weeks; median, 7.5 weeks). Among 19 patients, 16 patients (85%) had not shown typical symptoms of anti-NMDAR encephalitis four weeks after symptom onset, and three patients recovered within the first 4 weeks of onset after treatment with immunotherapy. The remaining three patients could not be assessed because of insufficient information.
Discussion
Diversity of Clinical Characteristics
The manifestations of anti-NMDAR antibody positivity are heterogeneous. Atypical presentations associated with anti-NMDA receptor antibody positivity occurred over a wide age range in both men and women and presented with diverse psychiatric/cognitive and/or neurological/motor symptoms. It was frequently associated with other autoimmune diseases. There were various forms of abnormal brain MRI, CSF, and EEG results in atypical cases as observed in typical cases. Patients who presented with psychiatric/cognitive symptoms with few or no neurological/motor symptoms had at least one of the following symptoms: memory impairment, catatonia, or abnormal MRI or EEG results. Although early diagnosis and implementation of appropriate immunotherapy might have prevented the disease from progressing to typical presentations in some cases, most patients (85%) in the selected case reports/series had not presented with typical symptoms of anti-NMDAR encephalitis four weeks after symptom onset. However, all atypical cases of anti-NMDAR encephalitis are probably not published systematically.
Response to Immunotherapy
Given the 95% response rate in our review, immunotherapy seems to be as effective in atypical cases as in typical cases. Ten patients (48%) responded to first-line immunotherapy (steroids, intravenous immunoglobulin, and plasmapheresis). Of note, this study may have a publication bias. Clinicians are more likely to report patients who have good clinical outcomes. One of the main reasons for this is that if a patient does not respond to immunotherapy, the clinician is less likely to interpret that antibody as pathogenic in that patient and would not consider these cases to be anti-NMDAR encephalitis.
Detection of Anti-NMDAR Antibodies
Based on our literature review, the presence of anti-NMDAR antibodies in both serum and CSF should be examined to expedite the detection and subsequent treatment of this treatable disorder. We recommend a lumbar puncture for patients with memory impairment, catatonia, or abnormal MRI or EEG results even if these patients do not show neurological/motor symptoms. In some cases, anti-NMDAR antibodies in the CSF were positive, whereas serum antibodies were negative. A previous study showed that the sensitivity of NMDA receptor antibody testing is higher in the CSF than in serum.26,27 Caution is advised when interpreting a positive serum result for anti-NMDAR antibody detection in the absence of CSF inflammatory findings or autoantibody detection in the CSF.28 However, the greatest challenge in real-world clinical settings in psychiatric hospitals is the difficulty in conducting lumbar puncture because of the technical expertise required or the patients’ uncooperative behavior because of their psychiatric symptoms.
Definition of Atypical Presentations
The definition of atypical presentations associated with anti-NMDA receptor antibody positivity used in this study may have advantages and disadvantages. We defined cases without seizure, involuntary movement, hypoventilation, and tumor as atypical presentations because primary psychiatric disorders typically are not associated with these symptoms or tumor, and we had a strong awareness of excluding the classic symptoms of anti-NMDAR encephalitis and evaluating the efficacy of immunotherapy without tumor resection. However, the presence of tumor is sex and age dependent.4,29 A very small percentage of young males with anti-NMDAR encephalitis present with a tumor. Furthermore, tumors may not be a criterion tested for in primary psychiatric presentations and can be asymptomatic. Currently, more patients are being diagnosed and treated earlier compared with a few years ago and therefore may not develop hypoventilation. We included cases with a decreased level of consciousness (stupor), speech disorders, or autonomic imbalance because primary psychiatric disorders with catatonia produce those symptoms.30 However, our inclusion criteria might be overly restrictive. Some case reports were not included despite reporting atypical presentations of anti-NMDAR encephalitis: a case with seizure and parkinsonism including micrographia,31 a case with IgM NMDAR antibody associated encephalitis mimicking bipolar disorder,32 two cases with intellectual disability and autism presenting with seizure and malignant catatonia,33 a case with fever of unknown origin, catatonia, mood disorder and ovarian teratoma,34 and two cases with autobiographical age awareness disturbance syndrome with seizure or involuntary movement.35 Because we excluded case series and cohort studies without individual case reports, nine cases of acute psychosis without clear clinical neurological involvement or seizure that were treated with immunotherapy36 were not included. Of these nine patients, six patients achieved symptomatic remission, and two patients responded clinically. However, the clinical characteristics, abnormal test results, immunotherapy, and outcome of each patient were not determined.
Conclusions
Because psychiatrists are often consulted for anti-NMDAR encephalitis patients, psychiatrists should be aware of the atypical presentations of anti-NMDAR encephalitis and consider it during the differential diagnosis of patients with memory impairment, catatonia, or abnormal MRI or EEG results, and consult with neurologists without hesitation. If not appropriately diagnosed, patients can be exposed to a prolonged period of psychotropic drug treatment, which have a number of side effects, and the chance of recovery may decrease. As with typical anti-NMDAR encephalitis cases, atypical cases present with psychiatric symptoms and behavior disorders with a high frequency at an early stage or throughout the disease course.
References
1.
Dalmau J, Tüzün E, Wu HY, et al: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61:25–36
2.
Dalmau J, Gleichman AJ, Hughes EG, et al: Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091–1098
3.
Dalmau J, Lancaster E, Martinez-Hernandez E, et al: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10:63–74
4.
Titulaer MJ, McCracken L, Gabilondo I, et al: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12:157–165
5.
Kayser MS, Titulaer MJ, Gresa-Arribas N, et al: Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013; 70:1133–1139
6.
Senda M, Bessho K, Oshima E, et al: Anti-inflammatory therapy and immunotherapy were partially effective in a patient with anti-N-methyl-D-aspartate receptor antibodies and a special subgroup of treatment-resistant schizophrenia. J Clin Psychopharmacol 2016; 36:92–93
7.
Zandi MS, Irani SR, Lang B, et al: Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011; 258:686–688
8.
Suzuki H, Samukawa M, Kitada M, et al: A case of anti-N-methyl-D-aspartate receptor encephalitis with systemic sclerosis. Eur J Neurol 2011; 18:e145–e146
9.
Lekoubou A, Viaccoz A, Didelot A, et al: Anti-N-methyl-D-aspartate receptor encephalitis with acute disseminated encephalomyelitis-like MRI features. Eur J Neurol 2012; 19:e16–e17
10.
Lebon S, Mayor-Dubois C, Popea I, et al: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder in an adolescent. J Child Neurol 2012; 27:1607–1610
11.
Yuan N, Glezer A: A young woman presenting with psychotic and mood symptoms from anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis: an emerging diagnosis. Int J Psychiatry Med 2013; 46:407–415
12.
Yau ML, Fung EL: Early consideration of anti-NMDAR encephalitis in unexplained encephalopathy. Hong Kong Med J 2013; 19:362–364
13.
Tüzün E, Türkoğlu R, Yumerhodzha SM, et al: Anti-N-methyl-D-aspartate receptor encephalitis with minimal cortical impairment. Neurol Sci 2013; 34:111–113
14.
Leypoldt F, Titulaer MJ, Aguilar E, et al: Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology 2013; 81:1637–1639
15.
Kuppuswamy PS, Takala CR, Sola CL: Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. Gen Hosp Psychiatry 2014; 36:388–391
16.
Finke C, Mengel A, Prüss H, et al: Anti-NMDAR encephalitis mimicking HaNDL syndrome. Cephalalgia 2014; 34:1012–1014
17.
Byrne S, McCoy B, Lynch B, et al: Does early treatment improve outcomes in N-methyl-D-aspartate receptor encephalitis? Dev Med Child Neurol 2014; 56:794–796
18.
Takeda A, Shimada H, Tamura A, et al: A case of anti-N-methyl-D-aspartate receptor encephalitis with multiple sclerosis-like demyelinated lesions. Mult Scler Relat Disord 2014; 3:391–397
19.
Fleischmann R, Prüss H, Rosche B, et al: Severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor in a patient with multiple sclerosis. JAMA Neurol 2015; 72:96–99
20.
Cuende E, Ruiz L: Anti-NMDA receptor encephalitis in a patient with rheumatoid arthritis. J Rheumatol 2015; 42:140
21.
Kruse JL, Lapid MI, Lennon VA, et al: Psychiatric autoimmunity: N-methyl-D-aspartate receptor IgG and beyond. Psychosomatics 2015; 56:227–241
22.
Sühs KW, Wegner F, Skripuletz T, et al: Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis. Exp Ther Med 2015; 10:1283–1292
23.
Orengo JP, Pekmezci M, Cree BA: Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis. Neurol Neuroimmunol Neuroinflamm 2015; 2:e101
24.
Gahr M, Lauda F, Wigand ME, et al: Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania. BMJ Case Rep 2015; 2015:2015
25.
Lalanne L, Jantzi C, Gorse A, et al: Melancholia associated with severe cognitive disorders as the expression of late-onset postpartum anti-N-methyl-D-aspartic acid receptor limbic encephalitis. J Neuropsychiatry Clin Neurosci 2015; 27:e168–e169
26.
Gresa-Arribas N, Titulaer MJ, Torrents A, et al: Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13:167–177
27.
Wang R, Guan HZ, Ren HT, et al: CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis. Seizure 2015; 29:137–142
28.
Titulaer MJ, Dalmau J: Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia: a theory with unproven links. Mol Psychiatry 2014; 19:1054
29.
Goldberg EM, Titulaer M, de Blank PM, et al: Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. Pediatr Neurol 2014; 50:181–184
30.
Bush G, Fink M, Petrides G, et al: Catatonia: I, rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129–136
31.
Kadoya M, Kadoya A, Onoue H, et al: An atypical case of Anti-NMDA receptor encephalitis: predominant Parkinsonism and persisting micrographia without oro-facial dyskinesia. Intern Med 2015; 54:1927–1932
32.
Choe CU, Karamatskos E, Schattling B, et al: A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res 2013; 208:194–196
33.
Kiani R, Lawden M, Eames P, et al: Anti-NMDA-receptor encephalitis presenting with catatonia and neuroleptic malignant syndrome in patients with intellectual disability and autism. BJPsych Bull 2015; 39:32–35
34.
Hur J: Fever of Unknown Origin: An Unusual Presentation of Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Infect Chemother 2015; 47:129–132
35.
Kuroda T, Futamura A, Sugimoto A, et al: Autobiographical age awareness disturbance syndrome in autoimmune limbic encephalitis: two case reports. BMC Neurol 2015; 15:238
36.
Zandi MS, Deakin JB, Morris K, et al: Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series. Schizophr Res 2014; 160:193–195
Information & Authors
Information
Published In
History
Received: 18 May 2016
Revision received: 29 June 2016
Accepted: 21 September 2016
Published online: 25 January 2017
Published in print: Summer 2017
Keywords
Authors
Competing Interests
The authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).